OrbiMed reveals 9.97% stake in Yarrow Bioscience after merger, plus warrants for 4.7 million shares
YARW has more than doubled off its 52-week low of $14.025.
Summary
OrbiMed Advisors and affiliates report a 9.97% stake in Yarrow Bioscience acquired through the VYNE Therapeutics merger, including warrants for 4.7 million shares that could substantially increase ownership once exercisable.
Key Events · Ownership and Investor Activity · YARW
-
OrbiMed Acquires 9.97% Stake in Merger
As part of the VYNE Therapeutics merger on July 27, 2026, OrbiMed entities received 266,306 shares—representing 9.97% of the outstanding—making them the largest disclosed shareholder.
-
Warrants for 4.7M Shares with Blocker
OrbiMed also holds pre-funded warrants to purchase 4,668,372 shares at $0.0001 each, but a 9.99% beneficial ownership blocker prevents exercise. If the blocker were lifted, OrbiMed could control over 60% of the company.
-
Board Representation via Mona Ashiya
Direct influence over corporate decisions comes through Mona Ashiya, a member of OrbiMed Advisors, who serves on Yarrow's board of directors.
-
Lock-Up Restricts Immediate Sales
A 180-trading-day lock-up agreement prevents Ashiya from selling her shares, aligning her interests with long-term holders through early 2027.
Analysis · YARW · Life Sciences
With the VYNE Therapeutics merger closing on July 27, OrbiMed—a heavyweight in healthcare investing—now controls nearly 10% of Yarrow Bioscience. The position consists of 266,306 common shares and pre-funded warrants covering an additional 4.67 million shares, though a 9.99% blocker prevents immediate exercise. Deep institutional involvement is underscored by an OrbiMed member sitting on Yarrow's board, signaling potential sway over strategy. Because the warrants carry a $0.0001 exercise price, they are deeply in the money, creating significant overhang if the blocker is ever lifted or waived.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.9% of the 1666 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, YARW was trading at $37.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $100.7M. The 52-week trading range was $14.03 to $46.95. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.